CHMP1B

Across TCGA pan-cancer cohorts, CHMP1B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CHMP1B data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CHMP1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHMP1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LUSC, and UCEC are the cancer types where CHMP1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.148	0.696	.004	24	view →
LUSC	OS	Median	All	0.193	0.660	.006	6	view →
UCEC	DFS	Median	All	0.959	0.634	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CHMP1B–HNSC (DFS)

Open the HNSC breakdown →